Activation of Peroxisome Proliferator-Activated Receptor-γ Decreases Pancreatic Cancer Cell Invasion through Modulation of the Plasminogen Activator System
Authors:
Open Access
- 1 March 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 4 (3) , 159-167
Abstract
Cancer cell invasion and metastasis require the concerted action of several proteases that degrade extracellular matrix proteins and basement membranes. Recent reports suggest the plasminogen activator system plays a critical role in pancreatic cancer biology. In the present study, we determined the contribution of the plasminogen activator system to pancreatic cancer cell invasion in vitro. Moreover, the effect of peroxisome proliferator-activated receptor (PPAR)-γ ligands, which are currently in clinical use as antidiabetic drugs and interestingly seem to display antitumor activities, on pancreatic cancer cell invasion and the plasminogen activator system was assessed. Expression of components of the plasminogen activator system [i.e., urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1, and uPA receptor] was detected in six human pancreatic cancer cell lines. Inhibition of urokinase activity by specific synthetic compounds reduced baseline pancreatic cancer cell invasion. The PPAR-γ ligands 15-deoxy-Δ12,14-prostaglandin J2 and ciglitazone also attenuated pancreatic cancer cell invasion. This effect was abrogated by dominant-negative PPAR-γ receptors and pharmacologic PPAR-γ inhibitors. Moreover, activation of PPAR-γ by ligands increased plasminogen activator inhibitor-1 and decreased uPA levels in pancreatic cancer cells, and this was accompanied by a reduction in total urokinase activity. The present study shows that the plasminogen activator system plays an integral role in pancreatic cancer cell invasion in vitro. Activation of the nuclear receptor PPAR-γ by ligands reduced pancreatic cancer cell invasion, which was largely mediated by modulation of the plasminogen activator system. These findings further underscore the potential role of PPAR-γ ligands as therapeutic agents in pancreatic cancer. (Mol Cancer Res 2006;4(3):159–67)Keywords
This publication has 45 references indexed in Scilit:
- PPARγ as a therapeutic target for tumor angiogenesis and metastasisCancer Biology & Therapy, 2005
- Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancerExpert Opinion on Investigational Drugs, 2005
- COX and PPARPancreas, 2004
- The central role of fat and effect of peroxisome proliferator-activated receptor–γ on progression of insulin resistance and cardiovascular diseaseThe American Journal of Cardiology, 2003
- Peroxisome Proliferator-Activated Receptor γ Induces Pancreatic Cancer Cell ApoptosisBiochemical and Biophysical Research Communications, 2001
- Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelAOncogene, 1999
- PPARγ Ligand-Dependent Induction of STAT1, STAT5A, and STAT5B during AdipogenesisBiochemical and Biophysical Research Communications, 1999
- Thiazolidinediones Down-Regulate Plasminogen Activator Inhibitor Type 1 Expression in Human Vascular Endothelial Cells: A Possible Role for PPARγ in Endothelial FunctionBiochemical and Biophysical Research Communications, 1999
- Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2Biochemical and Biophysical Research Communications, 1996
- Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signallingNature, 1992